Agensys
Pioneering advanced treatments for cancer with innovative therapeutic antibodies and drug conjugates.
Pioneering advanced treatments for cancer with innovative therapeutic antibodies and drug conjugates.
Agensys is a pioneering biotechnology company focusing on the research and development of therapeutic human monoclonal antibodies and antibody-drug conjugates aimed at treating cancer. Established in 1997 and formerly known as UroGenesys, the company is headquartered in Santa Monica, California. Agensys has gained traction in the biotechnology and pharmaceutical industries, targeting various tumors, including prostate, pancreatic, and bladder cancers. In July 2007, the company secured a significant $41.30M Series D investment led by HBM Healthcare Investments, Jafco Ventures, Alta Partners, OrbiMed, Nextech Invest, Bear Stearns, Tekla Capital Management, Innovis Investments, Lombard Odier, and Duquesne Capital Management. Agensys has been a subsidiary of Astellas Pharma US, Inc. since December 18, 2007. The company's slogan reflects its core mission of innovating advanced treatments for cancer with innovative therapeutic antibodies and drug conjugates.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series D | $41.30M | 10 |
|
12 Jul 2007 |
| Debt Financing | $3.00M | - | 05 Mar 2003 | |
| Series C | $42.80M | - | 04 Mar 2002 | |
| Series B | $11.30M | - | 11 Oct 1999 | |
| Series A | $8.00M | - | 10 Nov 1997 |
No recent news or press coverage available for Agensys.
We care about your data, and we'd love to use cookies make your experience better.
